In response to the recent public opinion on Lianhua Qingwen products, Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) ( Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) ) said on the interactive platform on April 20 that the company had retained the evidence and reported the case to the relevant departments.
Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) said that the company will continue to track the development of the situation. For some acts of slandering the company and publishing false information, the company has retained evidence and reported to relevant departments, and will safeguard its legitimate rights and interests through legal means.
On April 17, Dr. clove published an article on “don’t take Lianhua Qingwen to prevent covid-19” on his official wechat. After analyzing many aspects, Dr. clove concluded that even Huaqing can’t achieve the effect of preventing covid-19 virus, and said: don’t take medicine indiscriminately without disease, even Huaqing is the same.
Previously, Wang Sicong forwarded an article on his microblog entitled “who” recommended “Lianhua Qingwen, who told you?” And wrote in the forwarding message that “the CSRC should strictly investigate Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) “, but then deleted the forwarding message.
On April 20, Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) fell 9.69% to 29.27 yuan / share
Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) intraday close to the limit. The company said that the R & D process of Lianhua Qingwen was only 15 days, which was inconsistent with the fact
